Microenvironment Metastasis Program News Today

This class of inhibitors has shown therapeutic promise in several cancer types, including chronic lymphocytic leukemia and Burkitt lymphoma

When cancer that starts in the body metastasizes to the brain, it is almost always lethal, in part because so few treatment options exist. Now a new study by Wistar scientists published in Nature Communications shows that a type of brain cell called astrocytes plays an important role in promoting brain metastasis by recruiting a specific subpopulation of immune cells.

Aging and age-related disorders pose a complex challenge to the biomedical research community. To better understand how senescence is regulated is of high significance to promote healthy aging and treat age-associated disorders.

Due to the development of resistance to chemotherapy and recurring tumors, patients with ovarian cancer often have low survival rates.

Immunotherapies have shown striking clinical benefit in the treatment of many cancers, especially when used in combination with chemotherapy.

Credit: The Wistar Institute PHILADELPHIA -- (April 1, 2021 -- Scientists at The Wistar Institute identified a new mechanism of transcriptional control of cellular senescence that drives the release of inflammatory molecules that influence tumor development through altering the surrounding microenvironment. The study, published in Nature Cell Biology, reports that methyltransferase-like 3 (METTL3) and 14 (METTL14) proteins moonlight as transcriptional regulators that allow for establishment of...

(1) BEDMINSTER, N.J., Jan. 15, 2021 /PRNewswire/ -- Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced a collaboration with The Wistar Institute, an international leader in biomedical research, to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context ...

Researchers Identify Link Between Ovarian Cancer, Metabolism by Angela Mohan on  January 12, 2021 at 5:24 PM Nature Cancer. Up to 60% of ovarian clear cell carcinomas (OCCC) have inactivating mutations in the ARID1A tumor suppressor gene. These mutations are known genetic drivers of this type of cancer, which typically does not respond to chemotherapy and carries the worst prognosis among all subtypes of ovarian cancer. The laboratory of Rugang Zhang, Ph.D., deputy director o...

Link between driver of ovarian cancer, metabolism opens up new therapeutic strategies ANI | Updated: Jan 12, 2021 11:45 IST Washington [US], January 12 (ANI): Mutations that inactivate the ARID1A gene in ovarian cancer increase utilisation of the glutamine amino acid making cancer cells dependent on glutamine metabolism, according to a study by The Wistar Institute published online in Nature Cancer. Researchers also showed that pharmacologic inhibition of g...